Aurobindo Pharma Ltd.
Snapshot View

View in App

Prices View details >>

502.15 -14.90 ▼-2.9%

26 September 2022, 04:12:41 PM
Volume: 1,109,035

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.aurobindo.com
Market Cap 29,417.05 Cr.
Enterprise Value(EV) 27,599.81 Cr. 2022-03
Financial Indicators
Earnings per share (EPS) 40.94 Trailing Twelve Months Ending 2022-06
Price-Earning Ratio (PE) 12.26 Trailing Twelve Months Ending 2022-06
Industry PE 30.55 Trailing Twelve Months Ending 2022-06
Book Value / Share 428.38 Trailing Twelve Months Ending 2022-06
Price to Book Value 1.17 Calculated using Price: 502.05
Dividend Yield 1.79 Period Ending 2022-03
No. of Shares Subscribed 58.59 Cr. 585,938,609 Shares
FaceValue 1
Company Profile
Aurobindo Pharma continues to be one of the world's fastest growing Active Pharmaceutical Ingredients (API) manufacturing companies, driven by cost leadership, flexibility to produce multiple products in the same manufacturing facilities and capabilities in various therapeutic domains. Its API business has ensured the profitability and growth of its formulations business through seamless vertical integration. Its API business is supported by technologically advanced research and development infrastructure, which develops new products and plays a role in the delivery of products to the market. It has built a strong presence in key therapeutic segments such as Central nervous system (CNS), cardiovascular (CVS), anti-retroviral (ARV), anti-diabetics, gastroenterology and antibiotics. Also, it is building a diversified pipeline in high-margin specialty generic formulations segment.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-2.88%
1 Week
-3.34%
1 Month
-8.68%
3 Month
-4.62%
6 Month
-30.02%
1 Year
-30.41%
2 Year
-34.96%
5 Year
-29.21%
10 Year
+613.79%

Ratios View Details >>

9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 36.79 35.29 32.51 27.57 22.99 18.47 18.62 27.81 11.52
Return on Capital Employed (%) 27.18 27.18 27.35 24.92 22.72 17.97 18.79 30.33 12.82
Return on Assets (%) 13.95 14.03 14.13 14.44 13.07 10.00 10.39 17.34 7.99

Balance Sheet View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Shh. Funds 2,606 3,750 5,156 7,287 9,372 11,680 13,891 16,825 21,930 24,576
Non Curr. Liab. 1,225 1,494 1,592 584 102 594 358 555 807 903
Curr. Liab. 3,431 4,220 6,136 7,840 6,606 8,666 12,021 11,385 10,665 8,156
Minority Int. 11 26 26 3 2 2 2 0 -1 -2
Equity & Liab. 7,273 9,490 12,910 15,714 16,082 20,942 26,271 28,765 33,401 33,633
Non Curr. Assets 3,136 3,859 4,611 5,420 6,875 8,764 10,939 12,352 13,578 15,510
Curr. Assets 4,137 5,631 8,299 10,294 9,206 12,178 15,332 16,413 19,824 18,123
Misc. Exp. not W/O
Total Assets 7,273 9,490 12,910 15,714 16,082 20,942 26,271 28,765 33,401 33,633

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-06 Rs. Cr. TTM
Net Sales 8,100 12,121 13,795 14,910 16,463 19,564 23,099 24,775 23,455 23,989
Other Income 22 97 204 116 102 155 192 381 323 251
Total Income 8,121 12,217 13,998 15,025 16,565 19,719 23,290 25,155 23,778 24,241
Total Expenditure -5,966 -9,557 -10,607 -11,475 -12,691 -15,612 -18,234 -19,441 -19,071 -19,876
PBIDT 2,155 2,660 3,392 3,550 3,874 4,107 5,056 5,714 4,707 4,365
Interest -310 -160 -257 -67 -78 -263 -305 -74 -49 -50
Depreciation -313 -333 -392 -428 -558 -668 -967 -1,055 -1,127 -1,126
Taxation -363 -597 -721 -760 -818 -727 -899 -2,010 -726 -637
Exceptional Items -88 -26 2,815 -128 -128
PAT 1,169 1,571 2,022 2,296 2,420 2,362 2,859 5,389 2,678 2,424
Minority Interest 4 5 2 0 0 0 1 1 1 1
Share Associate 1 5 3 3 -15 -55 -31 -26
Other Related Items
Consolidated Net Profit 1,173 1,576 2,025 2,302 2,423 2,365 2,845 5,335 2,648 2,399
Adjusted EPS 20 27 35 39 41 40 49 91 45 41

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 275 646 1,237 1,420 3,279 1,955 1,651 4,381 3,329 5,016
Cash Fr. Inv. -246 -819 -1,398 -1,445 -1,787 -1,927 -2,903 -1,568 599 -3,212
Cash Fr. Finan. 108 118 93 365 -1,915 864 1,919 -1,947 -1,365 -2,969
Net Change 137 -55 -68 340 -424 892 667 866 2,563 -1,164
Cash & Cash Eqvt 203 148 461 744 320 1,210 1,876 2,747 5,330 4,163

Shareholding Pattern View Details >>

9 Qtrs 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%)
Promoter 52.01 52.01 51.94 51.94 51.83 51.83 51.83 51.83 51.83
Public 47.99 47.99 48.06 48.06 48.17 48.17 48.17 48.17 48.17
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 6.17 9.34 9.27 22.81 20.66 22.98 22.97 14.05 14.97

Announcements View Details >>

Fri, 23 Sep 2022
General updates
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and further to our above referred letter, this is to inform you that: The plant at Raleigh, North Carolina, USA owned by Aurolife Pharma LLC, a wholly owned step-down subsidiary of the Company, has received an establishment inspection report (EIR) mentioning the inspection a voluntary action initiated (VAI) from the United States Food and Drug Administration (US FDA) and with this, the US FDA pre-approval inspection and GMP inspection are concluded.
Fri, 23 Sep 2022
Loss of share certificate
We bring to your kind notice that the Company has received the letters from some of the shareholders informing about the loss of share certificates and also requested for issue of duplicate share certificates.
Fri, 23 Sep 2022
Schedule of Analysts/Institutional Investor Meet/Con. Call
This is to inform you that the representatives of the Company will be interacting in person with a group of healthcare investors from India / Asia, in the Corporate Office of Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company at 279 Princeton Hightstown Road, East Windsor, NJ 08520 on September 23, 2022 between 11:00 am ??? 12:00 noon (EST).

Technical Scans View Details >>

Mon, 26 Sep 2022
Close Crossing Last Week Low Close Crossing Last Week Low
Close Crossing 52 Week Low Close Crossing 52 Week Low
Closing Below Previous Low Closing Below Previous Low
Closing Below Previous Low for 3 days Closing Below Previous Low for 3 days
Making Lower Lows for 3 days Making Lower Lows for 3 days

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 216,444.01 900.70 -2.2%
Divi's Laboratories Ltd. 97,676.51 3,670.00 +0.8%
Cipla Ltd. 85,998.13 1,065.65 -0.2%
Dr. Reddy's Laboratories Ltd. 68,714.69 4,127.85 -0.3%
Apollo Hospitals Enterprise Ltd. 61,530.49 4,282.70 -3.1%
Torrent Pharmaceuticals Ltd. 51,200.03 1,512.80 -0.2%
Max Healthcare Institute Ltd. 40,653.72 419.25 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-06 55.65 900.70 -2.2%
Divi's Laboratories Ltd. Consolidated 2022-06 31.45 3,670.00 +0.8%
Cipla Ltd. Consolidated 2022-06 34.59 1,065.65 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-06 23.00 4,127.85 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-06 69.65 4,282.70 -3.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-06 64.10 1,512.80 -0.2%
Max Healthcare Institute Ltd. Consolidated 2022-06 64.55 419.25 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-06 4.32 900.70 -2.2%
Divi's Laboratories Ltd. Consolidated 2022-06 7.86 3,670.00 +0.8%
Cipla Ltd. Consolidated 2022-06 4.00 1,065.65 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-06 3.40 4,127.85 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-06 10.35 4,282.70 -3.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-06 8.03 1,512.80 -0.2%
Max Healthcare Institute Ltd. Consolidated 2022-06 6.33 419.25 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.02 900.70 -2.2%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,670.00 +0.8%
Cipla Ltd. Consolidated 2022-03 0.04 1,065.65 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,127.85 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,282.70 -3.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,512.80 -0.2%
Max Healthcare Institute Ltd. Consolidated 2022-03 0.12 419.25 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 900.70 -2.2%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,670.00 +0.8%
Cipla Ltd. Consolidated 2022-03 13.10 1,065.65 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,127.85 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,282.70 -3.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,512.80 -0.2%
Max Healthcare Institute Ltd. Consolidated 2022-03 10.19 419.25 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 900.70 -2.2%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,670.00 +0.8%
Cipla Ltd. Consolidated 2022-03 13.10 1,065.65 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,127.85 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,282.70 -3.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,512.80 -0.2%
Max Healthcare Institute Ltd. Consolidated 2022-03 10.19 419.25 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 900.70 -2.2%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,670.00 +0.8%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,065.65 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,127.85 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,282.70 -3.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,512.80 -0.2%
Max Healthcare Institute Ltd. Consolidated 2022-03 3,931.46 419.25 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 900.70 -2.2%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,670.00 +0.8%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,065.65 -0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,127.85 -0.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,282.70 -3.1%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,512.80 -0.2%
Max Healthcare Institute Ltd. Consolidated 2022-03 605.05 419.25 -1.8%

FAQ's On Aurobindo Pharma Ltd.

What is Aurobindo Pharma share price?
Can I buy Aurobindo Pharma shares now?
What is the Dividend Yield of Aurobindo Pharma?
What is the Market Cap of Aurobindo Pharma?
What are the key metrics to analyse Aurobindo Pharma?
What is the 52 Week High and Low of Aurobindo Pharma?
What is the trend of Aurobindo Pharma share price?